Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...

MSD has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in the US state of Delaware.

Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced compelling results from a new study demonstrating the ability of the Cellworks Platform ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE <li /> Q1 2025 net sal ...

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors ATLANTA, GA - April 29, 2025 (NEWMEDIAWIRE) - GeoVax ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Flatiron Health today announced its presence at ISPOR?The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron ...